Evidence map›Paper›PMID 22613460›Full record

ArticleExperimental and molecular pathology2012

The cholangiocyte marker, BD. 1, forms a stable complex with CLIP170 and shares an identity with eIF3a, a multifunctional subunit of the eIF3 initiation complex.

David R Mills, Rebecca A Rozich, Donna L Flanagan, Kate E Brilliant, DongQin Yang, Douglas C Hixson

Abstract read
In one paragraph

Article in Experimental and molecular pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

David R MillsDepartment of Medicine, Division of Hematology and Oncology, Rhode Island Hospital/The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA. David_Mills@Brown.edu
Rebecca A Rozich
Donna L Flanagan
Kate E Brilliant
DongQin Yang
Douglas C Hixson
Brown University · USRhode Island Hospital · US

Funding

UCP2 expression in colon cancerP20RR017695 · NCRR · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI MILLS, DAVID · 2002 to 2011
$15.0M
COBRE Center for Cancer Research DevelopmentP20GM103421 · NIGMS · RHODE ISLAND HOSPITAL · PI RAMRATNAM, BHARAT · 2012 to 2013
$4.5M
Genesis of Liver Carcinomas with Oval Cell TraitsR01CA093840 · NCI · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI MILLS, DAVID · 2002 to 2011
$3.1M
CELLULAR ORIGINS OF LIVER CANCERR01CA042715 · NCI · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI HIXSON, DOUGLAS CARTER · 1985 to 2008
$2.3M
NCI NIH HHS CA42715NCI NIH HHS CA93840NCI NIH HHS R01 CA042715NCI NIH HHS R01 CA093840NCRR NIH HHS P20 RR 017695NCRR NIH HHS P20 RR017695NIGMS NIH HHS P20 GM103421NIGMS NIH HHS P20GM103421
6 · The paper itself

Abstract

We have previously described the generation of a monoclonal antibody recognizing a novel cholangiocyte marker, designated BD.1, that is expressed by fetal and adult rat cholangiocytes but not hepatocytes or the hepatic progenitor cells known as oval cells. In the present report, we have undertaken a comprehensive examination of BD.1 expressed by long-term cultures of bile duct epithelial cells (BDEC) and prostate epithelial cells (PEC). We show that with continued passage, the levels of BD.1 expressed by BDEC and PEC drop significantly, a decrease that is temporally associated with transition from a diploid to an aneuploid karyotype. Cell cycle analysis revealed cell cycle dependent expression of BD.1 characterized by decreased BD.1 levels within the first 10 h after release from serum starvation followed by reacquisition as cells entered S phase. MAb BD.1 recognized a 170 kDa protein in Western blots and showed strong reactivity with a 170 kDa band in blots prepared from phosphoproteins isolated by metal affinity chromatography. Analysis by mass spectrometry of tryptic peptides generated from BD.1 purified by continuous elution electrophoresis identified the plus end microtubule-binding protein, CLIP170, in the fraction reactive with MAb BD.1. Double immunofluorescence with MAb BD.1 and a MAb specific for CLIP170 showed that both were reactive with intrahepatic bile ducts. However, overexpression or siRNA knockdown of CLIP170 in 293T cells did not significantly alter BD.1 levels, indicating that CLIP170 and BD.1 were distinct, co-migrating proteins. Immunoprecipitation analysis with MAb BD.1 and anti-CLIP170 antibodies showed that under microtubule depolymerizing conditions the two proteins could be co-precipitated with both antibodies, leading us to conclude they were capable of forming stable complexes. Two different protocols were devised to enrich for the CLIP170 binding protein recognized by MAb BD.1. Analysis of tryptic peptides by LC-ESI-MS/MS identified BD.1 as eIF3a, the largest subunit of the elongation initiation factor 3 (eIF3) complex. This identity was confirmed by the simultaneous knockdown of both BD.1 and eIF3a by eIF3a-specific siRNAs and by the strong reactivity of MAb BD.1 with the 170 kDa protein immunoprecipitated with the anti-eIF3a antibody, 5H10. Based on these findings, we concluded that the BD.1 antigen was identical to eIF3a, a multifunctional subunit of the eIf3 complex shown here to associate with microtubules through its interactions with CLIP170.

Indexed as

AnimalsAntibodies, MonoclonalBile DuctsBiomarkersCell CycleCells, CulturedCell SeparationEpithelial CellsEukaryotic Initiation Factor-3Flow CytometryGene Knockdown TechniquesMaleMicrotubule-Associated ProteinsMicrotubulesNeoplasm ProteinsPeptide MappingAntibodies, MonoclonalBiomarkerscytoplasmic linker protein 170EIF3A protein, humanEukaryotic Initiation Factor-3Microtubule-Associated ProteinsNeoplasm ProteinsRNA, Small Interfering

Identifiers

PMID22613460
PMCPMC4035227
OpenAlexW2016423613

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.